...led by MasterLux with participation from Columbus Life Science Fund II, a fund managed by Columbus Venture Partners...

...NYSE:CTLT) and Viralgen Vector Core, a Spain-based JV between Asklepios Bio Pharmaceutical Inc. (AskBio) and Columbus Venture Partners...

...NYSE:CTLT) and Viralgen Vector Core, a Spain-based JV between Asklepios Bio Pharmaceutical Inc. (AskBio) and Columbus Venture Partners...

...led by Caixa Capital Risc. The round included two other first-time backers, Spanish venture firms Columbus Venture Partners...

...to €250 million ($279 million) -- plus new VC entrants like Alta Life Sciences and Columbus Venture Partners...

...Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) via Baxalta Inc. and Shire plc. In 2017, Asklepios and Columbus Venture Partners...

...Bioscience plc (LSE:ARIX), Lundbeckfonden Ventures, Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, Columbus Venture Partners...

...Existing investors also participated, including Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, Columbus Venture Partners...

...Existing investors also participated, including Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, Columbus Venture Partners...

...for rare diseases Foundation for Applied Medical Research Gene / cell therapy; endocrine / metabolic Columbus Venture Partners...